Samsung Bioepis Signs a Collaboration Agreement with Samil Pharma to Co-Commercialize SB15 (biosimilar, aflibercept) for the Treatment of Ophthalmologic Conditions

Shots:  

• Samsung Bioepis entered into a collaborative agreement with Samil Pharmaceuticals to co-commercialize SB15, a biosimilar version for Eylea (aflibercept) for the treatment of wet age-related macular degeneration (wAMD) & diabetic macular edema (DME) across Korea  

• Earlier in Jun 2022, both companies had collaborated to jointly commercialize Amelivu, a biosimilar version of Lucentis for the treatment of AMD, DME, DR, mCNV & RVO, across the Korean market 

• From Jun 2020 to Mar 2022, Samsung Bioepis conducted a P-III clinical trial for SB15 in patients (n=449) with nAMD across 10 countries incl. the US and Korea 

Ref: Samsung Bioepis  | Image: Samsung Bioepis| Press Release

Related News:- Rani Therapeutics Reports the Results for RT-111 Capsules Containing CT-P43 (biosimilar, ustekinumab) in P-I Trial for the Treatment of Various Indications

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com